H. Lundbeck gets antitrust OK on Chelsea buyout; Pfizer among best at banking offshore profits; Hamburg gets a new boss;

@FiercePharma: Ranbaxy decision shows why FDA reluctant to rely on European inspections. More | Follow @FiercePharma

@TracyStaton: Would you pay $84K for Sovaldi yourself if you had hep C? LinkedIn discussion | Follow @TracyStaton

@EricPFierce: More action in sterile injectables. Amneal said to be trying to buy India's Epsilon Pharmaceuticals. Story | Follow @EricPFierce

@CarlyHFierce: Still trending on FierceVaccines: The top 10 best-selling vaccines of 2013. Report | Follow @CarlyHFierce

@JustinHFierce: Because mad cow disease is scary, when you actually think about it. Article | Follow @JustinHFierce

> FDA Commissioner Margaret Hamburg has a new boss after the Senate Thursday confirmed Sylvia Mathews Burwell, the former director of the OMB, as the head of the Department of Health and Human Services. Story

> China-focused Luqa Pharmaceuticals is now selling drugs in Hong Kong. Release

> Chelsea Therapeutics ($CHTP) announced that the waiting period under the Hart-Scott-Rodino Antitrust Act has expired, indicating U.S. regulators see no reason its merger with H. Lundbeck should not go forward. Release

> A new report says Pfizer ($PFE) last year ranked third of all the Fortune 500 companies when it comes to booking profits in offshore havens with $69 billion booked in foreign subsidiaries. Story

> Strides Arcolab has gotten FDA approval to market methoxsalen capsules for treating psoriasis, eczema and vitiligo skin disease. Story

> An advocacy group has complained to the FDA about a web page for a Novartis ($NVS) product called Denagard, an antibiotic it is promoting for treating dysentery and pneumonia and intestinal infections in swine. Blog post

Medical Device News

@FierceMedDev: London's Institute of Cancer Research to help develop MRI-guided radiation systems. More | Follow @FierceMedDev

@VarunSaxena2: A working group recommended $4.5 billion over 12 years in funding for NIH's BRAIN initiative. Story | Follow @VarunSaxena2

@MichaelGFierce: Singapore team designs nanotechnology glaucoma treatment for sustained release. Article | Follow @MichaelGFierce

@EmilyWFierce: New test that pinpoints multiple genes in a tumor could replace companion Dx as a tool for diagnosing cancer. Story | Follow @EmilyWFierce

> FDA beefs up cybersecurity efforts to ensure safety standards. More

> Kleiner Perkins, TPG-backed heart transplant monitor company files for $50M IPO. Story

Biotech News

@FierceBiotech: The search is on for 2014's Fiercest biotech startups. More | Follow @FierceBiotech

@JohnCFierce: ICYMI: Trevi, Complexa bag $38M in VC cash to hit the gas on R&D. Story | Follow @JohnCFierce

@DamianFierce: Follow @FiercePharma as @EricPFierce and @JonEPVantage wrap #ASCO14. Or tune in here: Twitter chat | Follow @DamianFierce

@EmilyMFierce: Collaborative KPI Therapeutics launches to beef up Kineta's pipeline. Article | Follow @EmilyMFierce

> Merck exec joins Novartis to helm oncology unit. Chutes & Ladders

> GW hits the FDA fast track with its cannabis-based epilepsy drug. More

> Pfenex eyes a $75M IPO to bankroll its biosimilars. Article

And Finally... A new review of past clinical trials finds that when treating women for acne, birth control pills work better than antibiotics. Story

Suggested Articles

AstraZeneca and Brazil have expanded their deal for a possible COVID-19 vaccine, this time to the tune of $360 million.

Novavax expects to churn out enough vaccines in 2021 to meet U.S. demand; experts slam the medical and political risks of Russia's unproven vaccine.

Novavax will have billions of doses of COVID-19 vaccine capacity next year and could single-handedly meet U.S. demand, executives said.